|Bid||51.83 x 0|
|Ask||51.88 x 0|
|Day's Range||50.74 - 52.97|
|52 Week Range||16.62 - 76.68|
|Beta (3Y Monthly)||2.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.94|
Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. Curaleaf Holdings has announced that it will release its third-quarter earnings results on November 26. Analysts expect Curaleaf Holdings to report revenue of 31.4 million Canadian dollars in the third quarter.
Why Canopy Growth Corp (TSX:WEED)(NYSE:CGC) might be a bargain before it reports on Wednesday.
One of the most anticipated aspects of Aurora Cannabis’s (ACB) (ACBFF) earnings results was an update on the recreational cannabis (HMMJ) market demand. In its press release, Aurora Cannabis stated that the company had a “strong performance” in the recreational cannabis segment during the quarter, which ended in September 2018. During the first quarter, the company stated that its brands accounted for nearly 30% of the total cannabis supplied through the OCS (Ontario Cannabis Store) with San Rafael being Aurora’s top brand sold in Ontario.
Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks releases a sector snapshot with a focus on the recent JV’’s (joint ventures) and investments in the cannabis infused beverage market.
Aurora Cannabis’s (ACB) (ACBFF) revenue rose by 260% year-over-year to 29.6 million Canadian dollars in the first quarter, which ended on September 2018. It’s important to note that the revenue included sales from recreational cannabis for the first time along with medical cannabis.
Canopy Growth (TSX:WEED)(NYSE:CGC) remains a smokin' hot buy. Here's why $100 is probable by year-end.
Aurora Cannabis (ACB) is estimated to report a loss per share of 0.07 Canadian dollars, which would be lower than the profit per share of 0.01 Canadian dollars in the corresponding quarter of 2017. Cronos (CRON) is expected to report a loss per share of 0.02 Canadian dollars, which is flat compared to the corresponding quarter a year ago. Tilray (TLRY) is expected to report a loss per share of 0.13 Canadian dollars for the quarter.
Here is why Tilray Inc. (NASDAQ:TLRY) is one of two top marijuana stocks that look attractive for the buy-and-hold investors.
Yesterday, we took a brief look at Aurora Cannabis’s (ACB) (ACBFF) first-quarter earnings for fiscal 2019 in How Aurora Cannabis Fared in the First Quarter. Aurora Cannabis stock fell ~4.5% during the regular market session after the company released its earnings. When stocks decline after an earnings release, it usually means that the earnings didn’t live up to the expectations priced into the stock and that the market corrected the stock price to realign its expectations with the latest information.
As we discussed earlier in this series, cannabis companies (MJ) are expected to report impressive sales growth and healthy margins. However, it’s important to see how these figures could impact cash flows and earnings.
Don't count on improvement in the U.S. legal environment for the cannabis industry with a new attorney general.
Aurora Cannabis reported fiscal first-quarter earnings, its first since the Canadian marijuana producer listed on the NYSE last month.
For now, that only includes dried flower, capsules and sprays, but the Canadian government said it would expand that to include edibles and concentrates like vape pens within a year. Justin Trudeau’s Liberal government will probably act sooner, before next year’s federal election, said Cam Battley, chief corporate officer at Aurora. “I suspect we’ll see regulations allowing for at least some of those products and maybe all of those products coming sooner than a year from now,” Battley said on the company’s fiscal first-quarter earnings call Monday.
Aurora Cannabis (ACB) (ACB-NYSE) reported its Q1 2019 earnings early today. The company reported revenue of 29.6 million Canadian dollars, which missed the consensus analyst estimate of 39.52 million Canadian dollars. However, its revenues grew by about 260% YoY from 8.3 million Canadian dollars in the corresponding quarter last year. The below chart shows analysts’ estimates for companies expected to report later this week.
Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is set to make an earnings announcement that will factor in legal pot shipments. Here's what to look for.
Cannabis companies (HMMJ) are expected to report impressive YoY revenue growth in the most recent quarter. Aurora Cannabis (ACB) and Canopy Growth (WEED) are expected to record sales growth in excess of 330% each. But how does this translate into margins?
Early on Monday, Aurora Cannabis (ACB)(ACB-NYSE) is estimated to report 39.5 million Canadian dollars in revenue. If the company meets the consensus estimates, it would be YoY growth of 379%. Cronos Group (CRON), which is expected to report its earnings on November 13, is estimated to report revenue of 3.6 million Canadian dollars, which would be YoY growth of 171% from the corresponding quarter in 2017.
Canopy Growth Corp (TSX:WEED)(NYSE:CGC) has emerged as a leader in the young cannabis market. Does it deserve to be in your RRSP?
Canopy Growth (CGC) is poised to gain from continued strength in the Canadian medical cannabis market in the fiscal second quarter.
Several major cannabis companies are set to release their quarterly earnings this week. Aurora Cannabis (ACB) (ACB-NYSE) is scheduled to be the first one in the group to report earnings on November 12 before the market opens. Tilray (TLRY), Cronos Group (CRON), Canopy Growth (WEED) (CGC), and CannTrust (CNTTF) also plan to release their earnings later this week.
Last week, the overall cannabis sector managed to remain in positive territory. The Horizons Marijuana Life Sciences ETF (HMMJ) gained nearly 3.5% between its close on November 2 and its close on November 9. The ETFMG Alternative Harvest ETF (MJ) also ended in positive territory with a 65-basis-point gain, and the Emerging Marijuana Growers Index ETF (HMJR) gained about 1.9% over the same period.
The public companies that grow and sell marijuana are getting heavy investor attention, but in an industry where share prices are so speculative, it’s tough to know which stocks are good buys.